sarmustine
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1999 (NCT00003703)
Timeline
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide
- 2-chloroethyl-3-sarcosinamide-1-nitrosourea
- 2-chloroethyl-3-sarcosinamide-1-nitrosourea
- n-chlorothylnitrosourea sarcosinamide
- sarcnu
- sarcnu
- sarcnu
- sarcnu
- sarmustine
- sarmustine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00028015 | Phase 2 | Oct 1, 2001 | Canadian Cancer Trials Group, CancerCare Manitoba |
| NCT00036660 | Phase 2 | Aug 1, 2001 | Canadian Cancer Trials Group, McGill University |
| NCT00004079 | Phase 1 | Aug 1, 1999 | Harvard University, National Cancer Institute (NCI) |
| NCT00003703 | Phase 1 | Jan 1, 1999 | McGill University, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 1 | 2001 |
| McGill University | Academic/Hospital | 2 | 1 | 2 | 1999 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 1999 |
| CancerCare Manitoba | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 1999 |
5 organizations
Page 1 / 1